These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 26135797)
1. Purple Glove Syndrome after Phenytoin or Fosphenytoin Administration: Review of Reported Cases and Recommendations for Prevention. Garbovsky LA; Drumheller BC; Perrone J J Med Toxicol; 2015 Dec; 11(4):445-59. PubMed ID: 26135797 [TBL] [Abstract][Full Text] [Related]
2. Fosphenytoin-induced purple glove syndrome: A case report. Newman JW; Blunck JR; Fields RK; Croom JE Clin Neurol Neurosurg; 2017 Sep; 160():50-53. PubMed ID: 28648954 [TBL] [Abstract][Full Text] [Related]
3. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. O'Brien TJ; Cascino GD; So EL; Hanna DR Neurology; 1998 Oct; 51(4):1034-9. PubMed ID: 9781525 [TBL] [Abstract][Full Text] [Related]
4. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. Coplin WM; Rhoney DH; Rebuck JA; Clements EA; Cochran MS; O'Neil BJ Neurol Res; 2002 Dec; 24(8):842-8. PubMed ID: 12500711 [TBL] [Abstract][Full Text] [Related]
5. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370 [TBL] [Abstract][Full Text] [Related]
6. Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department. Touchette DR; Rhoney DH Pharmacotherapy; 2000 Aug; 20(8):908-16. PubMed ID: 10939551 [TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of fosphenytoin for the treatment of status epilepticus. Popławska M; Borowicz KK; Czuczwar SJ Expert Rev Neurother; 2015; 15(9):983-92. PubMed ID: 26289487 [TBL] [Abstract][Full Text] [Related]
9. Phenytoin-Induced Purple Glove Syndrome: A Case Report and Review of the Literature. Okogbaa JI; Onor IO; Arije OA; Harris MB; Lillis RA Hosp Pharm; 2015 May; 50(5):391-5. PubMed ID: 26405326 [TBL] [Abstract][Full Text] [Related]
10. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy. Knapp LE; Kugler AR J Child Neurol; 1998 Oct; 13 Suppl 1():S15-8; discussion S30-2. PubMed ID: 9796747 [TBL] [Abstract][Full Text] [Related]
11. A prospective study of the incidence of the purple glove syndrome. Burneo JG; Anandan JV; Barkley GL Epilepsia; 2001 Sep; 42(9):1156-9. PubMed ID: 11580764 [TBL] [Abstract][Full Text] [Related]
12. Intramuscular use of fosphenytoin: an overview. Uthman BM; Wilder BJ; Ramsay RE Neurology; 1996 Jun; 46(6 Suppl 1):S24-8. PubMed ID: 8649611 [TBL] [Abstract][Full Text] [Related]
13. Early histopathologic changes in purple glove syndrome. Bhattacharjee P; Glusac EJ J Cutan Pathol; 2004 Aug; 31(7):513-5. PubMed ID: 15239684 [TBL] [Abstract][Full Text] [Related]
14. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Fischer JH; Patel TV; Fischer PA Clin Pharmacokinet; 2003; 42(1):33-58. PubMed ID: 12489978 [TBL] [Abstract][Full Text] [Related]
15. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. DeToledo JC; Ramsay RE Drug Saf; 2000 Jun; 22(6):459-66. PubMed ID: 10877039 [TBL] [Abstract][Full Text] [Related]